Epidemiology, pathological characteristics and survival of retroperitoneal soft‑tissue sarcomas compared with non‑retroperitoneal soft tissue sarcomas.

epidemiology retroperitoneal sarcoma soft tissue sarcoma survival

Journal

Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 02 12 2022
accepted: 15 03 2023
medline: 16 6 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

Retroperitoneal soft-tissue sarcomas (RPS) are rare forms of mesenchymal tumors that account for ~0.15% of all malignancies. The purpose of the present study was to determine the differences between RPS and non-RPS anatomopathological and clinical features and to analyze whether the hazard ratio for short-term mortality differs between patients with RPS and non-RPS, after adjusting for differences in baseline anatomopathological and clinical features. The Veneto Cancer Registry, a high-resolution population-based dataset spanning the regional population, was used as a data source for the analysis. The current analysis focuses on all incident cases of soft-tissue sarcoma recorded by the Registry from January 1, 2017 to December 31, 2018. A bivariate analysis was carried out to compare demographic and clinical characteristics in RPS and non-RPS. Short-term mortality risk was analyzed by primary tumor site. The significance of variations in survival by site group was determined using Kaplan-Meier curves and the Log-rank test. Finally, Cox regression was used to assess the hazard ratio for survival by sarcoma group. RPS accounted for 22.8% of the total sample (92 out of 404 cases). The mean age at diagnosis was 67.6 years for RPS vs. 63.4 for non-RPS; 41.3% of RPS were >150 mm vs. 5.5% for non-RPS. Stages III and IV were more prevalent in RPS (53.2 vs. 35.6%), despite the fact that, in both groups, advanced stages are the most common onset at diagnosis. Regarding surgical margins, the present study showed that R0 is the most prevalent in non-RPS (48.7%), while R1-R2 is the most frequent in patients with RPS (39.1%). The 3-year mortality rate for retroperitoneum was 42.9 vs. 25.7%. Comparing RPS and non-RPS, the multivariable Cox model showed a hazard ratio of 1.58 after adjusting for all other prognostic factors. RPS clinical and anatomopathological characteristics differ from those of non-RPS. Overall, despite adjusting for other prognostic factors, the retroperitoneum site was an independent prognostic factor associated with a worse overall survival in sarcoma patients compared with other sites.

Identifiants

pubmed: 37323817
doi: 10.3892/ol.2023.13887
pii: OL-26-1-13887
pmc: PMC10265397
doi:

Types de publication

Journal Article

Langues

eng

Pagination

301

Informations de copyright

Copyright: © Buja et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Ann Surg Oncol. 2015 Jan;22(1):256-63
pubmed: 25316486
Chirurg. 2022 Jan;93(1):16-26
pubmed: 34596706
Ann Surg. 2016 Mar;263(3):593-600
pubmed: 25915910
Ann Surg. 2014 Sep;260(3):416-21; discussion 421-2
pubmed: 25115417
Ann Surg Oncol. 2017 Dec;24(13):3880-3887
pubmed: 29058143
J Surg Oncol. 2016 Mar;113(3):270-6
pubmed: 26707028
Indian J Surg Oncol. 2012 Sep;3(3):215-21
pubmed: 23997509
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328
Eur J Surg Oncol. 2014 Dec;40(12):1662-70
pubmed: 25454827
Health Syst Transit. 2014;16(4):1-168
pubmed: 25471543
Ann Oncol. 2010 Feb;21(2):397-402
pubmed: 19622598
Cureus. 2020 Aug 21;12(8):e9913
pubmed: 32968575
J Gynecol Oncol. 2009 Sep;20(3):135-6
pubmed: 19809545
Cancer. 2012 Jul 1;118(13):3321-9
pubmed: 22246900
J Surg Res. 2007 Jul;141(1):105-14
pubmed: 17512548
Surg Clin North Am. 2016 Oct;96(5):901-14
pubmed: 27542634
Eur J Surg Oncol. 2017 Jul;43(7):1191-1198
pubmed: 28057392
Am J Clin Oncol. 2019 Feb;42(2):160-165
pubmed: 30394881
J Surg Res. 2011 Jun 15;168(2):e173-80
pubmed: 21470630
Mod Pathol. 2019 Apr;32(4):539-545
pubmed: 30397260
Br J Plast Surg. 1996 Jan;49(1):27-33
pubmed: 8705099
Surgery. 2016 Dec;160(6):1628-1635
pubmed: 27495850
Ann Surg. 2009 Dec;250(6):970-6
pubmed: 19644351

Auteurs

Alessandra Buja (A)

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, I-35131 Padua, Italy.

Massimo Rugge (M)

Department of Medicine, Pathology and Cytopathology Unit, University of Padua, I-35128 Padua, Italy.
Veneto Tumor Registry, Azienda Zero, I-35132 Padua, Italy.

Matteo Barillaro (M)

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, I-35131 Padua, Italy.

Andrea Miatton (A)

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, I-35131 Padua, Italy.

Saveria Tropea (S)

Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.

Claudia Cozzolino (C)

Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.

Manuel Zorzi (M)

Veneto Tumor Registry, Azienda Zero, I-35132 Padua, Italy.

Antonella Vecchiato (A)

Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.

Paolo Del Fiore (P)

Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.

Antonella Brunello (A)

Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.

Vincenzo Baldo (V)

Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, I-35131 Padua, Italy.

Carlo Riccardo Rossi (CR)

Department of Surgery, Oncology and Gastroenterology, University of Padua, I-35124 Padua, Italy.

Simone Mocellin (S)

Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, I-35128 Padua, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padua, I-35124 Padua, Italy.

Classifications MeSH